65,437 trials
Depression · Substance-Related Disorders
Primary: Change in Short Moods and Feelings Questionnaire (SMFQ) — 2.19; 1.21 units on a scale — p=<0.05
Non Small Cell Lung Cancer (NSCLC)
Primary: Percentage of Participants With Select Dermatologic Adverse Events of Interest (SDAEI) (All Causality, All Grade) in the First 8 Weeks of Treatment by Treatment Arm for…
Granulomatosis With Polyangiitis · Microscopic Polyangiitis
Primary: Incidence Rate of Serious Infections — 7.11 events per 100 patient year
Alzheimer's Disease
Primary: Clinical and Diagnostic Change in Patient Management — 68.0; 55.5 percentage of patients — p=0.002
Hepatitis B, Chronic
Primary: Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B — 25.7; 6 percentage of participants — p== 0.0043
Rheumatoid Arthritis
Primary: Percentage of Participant With Good or Moderate Response According to European League Against Rheumatism (EULAR) Response Criteria — 0; 8.20; 43.03; 9.00 percentage of…
Type 1 Diabetes Mellitus
Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 2 Year Visit — 0.375; 0.266 nmol/L — p=0.0014
Asthma
Primary: Change From Baseline in Morning Peak Expiratory Flow (PEF) — 15.23; 14.79; 17.37; 5.40 liters/minute — p=0.0116
Lipodystrophy
Primary: Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin — 8.4; 8.1; 6.6; 7.2 percentage of glycated hemoglobin — p=<0.001
Obesity · Eating Behavior
Primary: Calories Consumed Following the Experimental Manipulation — 647.5; 520.9 kcal
CHRONIC MYELOGENOUS LEUKEMIA
Primary: Rate of Confirmed Best Cumulative Complete Molecular Response (CMR) — 13; 6; 91; 97 Participants — p=0.1083
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Thrombosis · Cancer · Pulmonary Embolism
Primary: Number of Participants With Composite of Confirmed Major Bleeding and Clinically Relevant Nonmajor (CRNM) Bleeding — 1; 1; 1; 4 Participants
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response (SVR) — 23.8; 36.5 percentage of participants — p=0.0536
Diabetes Mellitus, Type 1
Primary: Mean Stimulated C-peptide Area Under the Curve — 0.28; 0.27; 0.25 pmol/ml — p=0.47